3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Dermatologic
1
Conditions
Melanoma
33
Neoplasms
18
Colorectal Neoplasms
3
Skin Neoplasms
2
Carcinoma, Non-Small-Cell Lung
2
Urinary Bladder Neoplasms
1
Thyroid Neoplasms
1
Solid Tumor
1
Skin Diseases
1
Neoplasms, Unknown Primary
1
Neoplasm Metastasis
1
Multiple Myeloma
1
Lymphoma
1
Diabetes Mellitus, Insulin-Dependent, 12
1
Colorectal Cancer Metastatic
1
Biliary Tract Neoplasms
1
Advanced BRAF-mutant Cancers
1
Interventions
binimetinib
2
Watchful Waiting
2
Aminolevulinic Acid
2
palbociclib
1
ipatasertib
1
exemestane
1
encorafenib
1
baricitinib
1
atezolizumab
1
Vemurafenib
1
VP-102
1
Trabectedin
1
Paclitaxel
1
Injections, Intradermal
1
Gonadotropin-Releasing Hormone
1
Everolimus
1
Dacarbazine
1
Cantharidin
1
BF-200 ALA
1
Anastrozole
1
AZD9833
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
INDUSTRY
×
Skin Diseases
×
Vemurafenib
×
Clear all
NCT01909453
2026-02-27
COLUMBUS
Pfizer
Phase 3
Completed
921 enrolled
48 charts
1 FDA